Radar›Companies›Pharmaceutical Preparations Stocks in USA: Revenue Cohort 19
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 19

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderTonix Pharma · 55
Strongest available pathPyxis Oncology · -75.1%
Widest latest marginEvofem · 1.9%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1TNXP · Nasdaq

Tonix Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007New York City, New York$233.1M market cap
View full Companies Radar profile
55Moderate
Snapshot price$13.59as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.01BTonix Pharmaceuticals Holding Corp.
Net margin-946.2%FY2025
P/E snapshot-1.7xone ratio, not a verdict
Prism attention32.6%share across these five
Filing track recordRevenue, USD billions
+68.7%
$0$0.0B$0.0B$0.0BFY2023: $0.008BFY2024: $0.010BFY2025: $0.013B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 29.9%
52-week position19% through range
$9.40$31.55
News mentions997
Community mentions0partial coverage
U.S.-scope patents325
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position8/100
Capital-event signal92/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2EVFM · OTC

Evofem

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2009San Diego, California$1.1M market cap
View full Companies Radar profile
48Cautious
Snapshot price$0.01as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.02BEvofem Biosciences, Inc.
Net margin1.9%FY2025
Prism attention19.2%share across these five
Filing track recordRevenue, USD billions
+10.8%
$0$0.0B$0.0B$0.0BFY2023: $0.018BFY2024: $0.019BFY2025: $0.020B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.3%
52-week position50% through range
$0.00$0.02
News mentions587
Community mentions121partial coverage
U.S.-scope patents70
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal50/100
Management stability90/100
Market position13/100
Capital-event signal72/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 12 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PYXS · Nasdaq

Pyxis Oncology

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2019Boston, Massachusetts$269.4M market cap
View full Companies Radar profile
36Cautious
Snapshot price$3.23as of page date
Monthly-close return-75.1%five-year window
FY2025 revenue$0.01BPyxis Oncology, Inc.
Net margin-574.5%FY2025
P/E snapshot-2.9xone ratio, not a verdict
Prism attention16.8%share across these five
Filing track recordRevenue, USD billions
-14.2%
$0$0.0B$0.0B$0.0BFY2024: $0.016BFY2025: $0.014B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.2%
52-week position49% through range
$1.03$5.55
News mentions515
Community mentions15partial coverage
U.S.-scope patents10
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position11/100
Capital-event signal52/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 3 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4EMMA · OTC

Emmaus Medical

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Torrance, California$5.8M market cap
View full Companies Radar profile
33Cautious
Snapshot price$0.08as of page date
Monthly-close return-94.6%five-year window
FY2025 revenue$0.01BEmmaus Life Sciences, Inc.
Net margin-60.2%FY2025
Prism attention6.4%share across these five
Filing track recordRevenue, USD billions
-39.6%
$0$0.0B$0.0B$0.0BFY2021: $0.021BFY2022: $0.018BFY2023: $0.030BFY2024: $0.017BFY2025: $0.012B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -11.8%
52-week position100% through range
$0.01$0.08
News mentions197
Community mentions0partial coverage
U.S.-scope patents49
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position10/100
Capital-event signal48/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CVSI · OTC

CV Sciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Las Vegas, Nevada$4.5M market cap
View full Companies Radar profile
31Cautious
Snapshot price$0.02as of page date
Monthly-close return-93.3%five-year window
FY2025 revenue$0.01BCV Sciences, Inc.
Net margin-6.9%FY2025
Prism attention25.0%share across these five
Filing track recordRevenue, USD billions
-31.2%
$0$0.0B$0.0B$0.0BFY2021: $0.020BFY2022: $0.016BFY2023: $0.016BFY2024: $0.016BFY2025: $0.014B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.9%
52-week position11% through range
$0.01$0.10
News mentions766
Community mentions0partial coverage
U.S.-scope patents21
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal34/100
Management stability90/100
Market position26/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Pyxis Oncology
-75.1%
CV Sciences
-93.3%
Emmaus Medical
-94.6%
Tonix Pharma
-100.0%
Evofem
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Evofem
$0.02B
Pyxis Oncology
$0.01B
CV Sciences
$0.01B
Tonix Pharma
$0.01B
Emmaus Medical
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Evofem
1.9%
CV Sciences
-6.9%
Emmaus Medical
-60.2%
Pyxis Oncology
-574.5%
Tonix Pharma
-946.2%

Prism news attention

Normalized share across these five names; attention is not quality.

Tonix Pharma
32.6%
CV Sciences
25.0%
Evofem
19.2%
Pyxis Oncology
16.8%
Emmaus Medical
6.4%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Tonix Pharma leads the conversation

It holds 32.6% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.01B.

Price path

Pyxis Oncology leads the available price paths

Its monthly-close return is -75.1% for the five-year window. At the other end, Evofem is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Evofem has the widest latest margin

Its FY2025 net margin is 1.9%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Pyxis Oncology shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -2.9x while its five-year window price return is -75.1%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · TNXP

Tonix Pharma

997available Prism news records

Prism top themes

Price action & investor response
54
Legal, arbitration & regulatory
23
Macro demand & rates
23
Capital allocation & transactions
12
Leadership & governance
5

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-41.0%144 latest 12m vs 244 prior 12m
2024-01: 11 mentions2024-02: 16 mentions2024-03: 12 mentions2024-04: 8 mentions2024-05: 7 mentions2024-06: 19 mentions2024-07: 21 mentions2024-08: 27 mentions2024-09: 23 mentions2024-10: 14 mentions2024-11: 15 mentions2024-12: 11 mentions2025-01: 9 mentions2025-02: 45 mentions2025-03: 25 mentions2025-04: 28 mentions2025-05: 16 mentions2025-06: 10 mentions2025-07: 4 mentions2025-08: 22 mentions2025-09: 11 mentions2025-10: 11 mentions2025-11: 12 mentions2025-12: 13 mentions2026-01: 13 mentions2026-02: 4 mentions2026-03: 22 mentions2026-04: 6 mentions2026-05: 23 mentions2026-06: 3 mentions2024-012026-06

Machine-classified coverage tone

95.7% positive+7.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 28stock price 17fibromyalgia syndrome techniques 14market momentum 14vaccine formulation 13market rally 12subunit vaccines 11viral vector vaccines 9

Keyword tag occurrences in available Prism news records.

Coverage: 2011-10-14–2026-06-12 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

EVFM

Evofem

121 mentions
Stock and valuation
67
Products, pricing and logistics
18

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 121 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

TNXP

Tonix Pharma

through 2026-03-03
Earnings releases 11Leadership changes 5Company announcements 3Listing / IPO 3Regulatory 3
  1. Regulatory

    Tonix Pharmaceuticals Holding Corp. has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market.

  2. Leadership changes

    Staying in the medical industry, Tonix Pharmaceuticals has named Irina Ishak as general counsel, leading the company’s legal, corporate governance and compliance functions.

  3. Earnings releases

    Net product revenue for the three months ended September 30, 2025 was approximately $3.3 million, compared to $2.8 million for the same period in 2024; revenue reflected combined net sales of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EVFM

Evofem

through 2026-02-07
Earnings releases 18M&A 11Leadership changes 5Business contracts 2
  1. M&A

    The company moved into the women’s health market with the $100 million planned acquisition of Evofem Biosciences Inc., maker of the contraceptive gel Phexxi, which it reported on Dec. 12.

  2. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evofem Biosciences $11.39 million 0.10 $52.98 million ($0.06) -0.15

  3. Business contracts

    including its July 2024 license agreement with Emirati pharmaceutical company Pharma 1 Drug Store, which plans to launch the hormone-free contraceptive vaginal gel in the UAE following approval by the Emirates Drug Establishment.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PYXS

Pyxis Oncology

through 2026-02-03
Earnings releases 8Company announcements 7Leadership changes 7Asset acquisitions 3M&A 2
  1. Leadership changes

    Thomas Civik, a member of Pyxis Oncology’s Board of Directors since the company’s IPO and a biotechnology executive, has been appointed Interim CEO, effective immediately.

  2. Earnings releases

    Net loss was $21.2 million, or ($0.35) per common share, for the quarter ended September 30, 2024.

  3. Company announcements

    Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EMMA

Emmaus Medical

through 2025-12-31
Earnings releases 7Company announcements 1Regulatory 1
  1. Regulatory

    Endari® is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman.

  2. Earnings releases

    Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2024.

  3. Company announcements

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CVSI

CV Sciences

through 2026-03-28
Earnings releases 21Business contracts 2M&A 2
  1. Earnings releases

    In the fourth quarter, revenue was $3.3 million versus $3.9 million in the year-ago quarter and was consistent with the third quarter of 2025.

  2. Business contracts

    Las Vegas-based CV Sciences (CVSI) announced Wednesday that its CBD oil will be sold in 945 Kroger-owned stores spanning 17 U.S. states.

  3. M&A

    CV Sciences, Inc. (OTCQB:CVSI), a prominent consumer wellness company focusing on hemp extracts and other science-backed natural ingredients, has completed the acquisition of Elevated Softgels, LLC.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 91–98. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Evofem and Evofem

Evofem has the largest displayed latest revenue at $0.02B; Evofem has the widest displayed latest margin at 1.9%.

Open Evofem in Companies Radar
Comparisons
Anomalies

CV Sciences has the widest attention-readiness rank gap

It ranks #2 by measured news attention (25.0%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open CV Sciences in Companies Radar

Tonix Pharma shows a price-operating divergence to inspect

Its displayed filing-revenue change is +68.7% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Tonix Pharma in Companies Radar
Explanations

Attention measures coverage volume, not quality

Tonix Pharma's 32.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Tonix Pharma in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Tonix Pharma's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 55/100 score.

Open Tonix Pharma in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon